Bayer Aktiengesellschaft (ETR:BAYN) Stock Price Down 0.4% - What's Next?

Key Points

• Bayer shares fell 0.4% in mid-day trading to €40.61, with about 2.69 million shares changing hands (previous close €40.79).
• The company shows a negative PE (-46.59) and high leverage (debt-to-equity 144.30) with a market cap around $41 billion, signaling valuation and balance-sheet concerns despite a 200-day moving average of €36.12.
• Bayer is a global life-sciences group operating across Pharmaceuticals, Consumer Health and Crop Science, offering prescription drugs, OTC products and agricultural solutions.

Bayer Aktiengesellschaft (ETR:BAYN - ) shares were down 0.4% during mid-day trading on Wednesday . The stock traded as low as €40.61 and last traded at €40.61. Approximately 2,691,182 shares changed hands during trading, The stock had previously closed at €40.79.

Bayer Aktiengesellschaft Stock Down 0.4%

The firm has a market capitalization of $41.00 billion, a PE ratio of -46.59, a PEG ratio of 36.39 and a beta of 0.93. The company has a fifty day moving average price of €41.21 and a 200-day moving average price of €36.12. The company has a debt-to-equity ratio of 144.30, a quick ratio of 0.72 and a current ratio of 1.00.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.